PTC Therapeutics Provides Update on German pricing and Reimbursement Process for Translarna™ (ataluren)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Wedbush Downgrades PTC Therapeutics (PTCT) to Neutral
March 1, 2016 7:29 AM ESTWedbush downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Neutral with a price target of $11.00 (from $27.00), saying lower Translarna estimates shift risk/reward.
Analyst Heather Behanna commented, "Though we still believe Translarna has a good chance of full EU approval, we are... More
Cowen Downgrades PTC Therapeutics (PTCT) to Market Perform
March 1, 2016 7:27 AM ESTCowen downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $7.98 yesterday.
... MoreGermany Seeks PTC Therapeutics (PTCT) Translarna Discount - Oppenheimer
February 29, 2016 9:32 AM ESTOppenheimer analyst, Christopher Marai, quantified PTC Therapeutics' (NASDAQ: PTCT) lost opportunity from a failed arbitration process in Germany. More detail will be on today's earnings call after the close but the analyst defines the scope to keep in context. No change yet to the Outperform rating.
PTC announced Friday that an arbitration process with German Federal Association of the Statutory Health Insurances (GKV-SV) concluded with an unacceptable decision. Authorities may have suggested as much as a 65% price reduction, though this is unconfirmed. PTCT is considering removing the drug from the German market;... More
